Tuesday | Wednesday | Wednesday (OnDemand) | Thursday | Friday
THURSDAY, DECEMBER 10, 2020
All times are CENTRAL Time    
8:30 am - 8:45 am CT WELCOME AND OVERVIEW  
  Virginia G. Kaklamani, MD
UT Health San Antonio
San Antonio, TX
 
     
8:45 am - 11:30 am CT GENERAL SESSION 3

Moderator: Ian E. Krop, MD, PhD
Dana-Farber Cancer Institute
Boston, MA
 
     
8:45 am CT GS3-00. SWOG S1007: adjuvant trial randomized ER+ patients who had a Recurrence Score < 25 and 1-3 positive nodes to endocrine therapy (ET) versus ET + chemotherapy  
  Kalinsky K, Barlow WE, Meric-Bernstam F, Gralow JR, Albain KS, Hayes D, Lin N, Perez EA, Goldstein LJ,Chia S, Dhesy-Thind S, Rastogi P, Alba E, Delaloge S, Martín M, Gil Gil M, Arce-Salinas C, Brain E, Park IH, Pierga J-Y, Hernandez Lluch A, Ramos Vasquez M, Ruiz Borrego M, Jung KH, Ferrero J-M, Schott A, Shak S, Sharma P, Lew DL, Miao J, Tripathy D, Hortobagyi G, Pusztai L. Emory University/SWOG, Atlanta, GA; SWOG Statistics and Data Management Center, Seattle, WA; University of Texas MD Anderson Cancer Center/SWOG, Houston, TX; University of Washington School of Medicine/Seattle Cancer Care Alliance/SWOG, Seattle, WA; Loyola University Chicago, Maywood, IL; University of Michigan, Ann Arbor, MI; Dana Farber Cancer Institute/Alliance for Clinical Trials in Oncology, Boston, MA; Mayo Clinic Jacksonville/Alliance for Clinical Trials in Oncology, Jacksonville, FL; Fox Chase Cancer Center/ECOG-ACRIN, Philadelphia, PA; BCCA-Vancouver Cancer Center/CCTG, Vancouver, BC; Juravinski Cancer Centre at Hamilton Health Sciences/CCTG, Hamilton, ON; University of Pittsburgh/NRG Oncology, Pittsburgh, PA; UGCI Medical Oncology Hospital Virgen de la Victoria. IBIMA, Malago, Spain; Institut Gustave Roussy/UNICANCER, Paris, France; Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain; L’Hospitalet, Barcelona, Spain; Instituto Nacional De Cancerologia de Mexico, Mexico City, Mexico; Institut Curie-Centre Rene Huguenin Saint Cloud, Saint Cloud, France; National Cancer Center-Korea, Goyang-si, Republic of Korea; Institut Curie Paris, Paris, France; Hospital Clinico Universitario de Valencia, Valencia, Spain; Centro Oncologico de Galicia, A Coruña, Spain; Hospital Universitario Virgen del Rocio, Sevilla, Spain; Universitiy of Ulsan College of Medicine, Seoul, Spain; Centre Antoine Lacassagne, Nice, France; Exact Sciences, Redwood City, CA; University of Kansas Medical Center, Kansas City, KS; Yale University, New Haven, CT.
 
     
9:00 am CT GS3-01.  Additional efficacy endpoints from the phase 3 KEYNOTE-355 study of pembrolizumab plus chemotherapy vs placebo plus chemotherapy as first-line therapy for locally recurrent inoperable or metastatic triple-negative breast cancer     
  Rugo HS, Schmid P, Cescon DW, Nowecki Z, Im S-A, Yusof MMd, Gallardo C, Lipatov O, Barrios CH, Perez-Garcia J, Iwata H, Masuda N, Torregroza Otero M, Gokmen E, Loi S, Guo Z, Zhao J, Karantza V, Aktan G, Cortes J. University of California San Francisco Comprehensive Cancer Center, San Francisco, CA; Barts Cancer Institute, Centre for Experimental Cancer Medicine, London, United Kingdom; Princess Margaret Cancer Centre, Toronto, ON, Canada; Maria Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology, Warsaw, Poland; Seoul National University Hospital, Seoul, Republic of Korea; Pantai Hospital, Kuala Lumpur, Malaysia; Arturo Lopez Perez Foundation, Santiago, Chile; Republican Clinical Oncology Dispensary, Republic of Bashkortostan, Russian Federation; Centro de Hematologia e Oncologia, Porto Alegre, Brazil; Institute of Breast Cancer, Quiron Group, Barcelona, Spain; Aichi Cancer Center Hospital, Nagoya, Japan; National Hospital Organization Osaka National Hospital, Osaka, Japan; Oncomedica S.A., Monteria, Colombia; Ege University Medical Faculty, Izmir, Turkey; Peter McCallum Cancer Institute, Melbourne, Australia; Merck & Co., Inc., Kenilworth, NJ; IOB Institute of Oncology, Quiron Group, Madrid & Barcelona, Spain.  
     
9:15 am CT GS3-02.  Patient-reported outcomes (PROs) from the Ph 3 IMpassion031 trial of neoadjuvant (NA) atezolizumab + chemo in early triple-negative breast cancer (eTNBC)  
  Mittendorf EA, Harbeck N, Zhang H, Saji S, Hae Jung K, Patel S, Patel S, Nguyen Duc A, Liste-Hermoso M, Chui SY, Barrios CH. Dana-Farber/ Brigham and Womens Cancer Center, Boston, MA; Breast Center, Ludwig-Maximilians-University (LMU), Munich, Germany; Memorial Sloan Kettering Cancer Center, New York, NY; Fukushima Medical University, Fukushima, Japan; Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea; Genentech, Inc., South San Francisco, CA; F. Hoffmann-La Roche, Ltd., Basel, Switzerland; Oncology Research Center, HSL, PUCRS, Porto Alegre, Brazil.  
     
9:30 am CT GS3-03.  Immunotherapy in metastatic TNBC   
  Discussant: Sylvia Adams, MD
New York University
Perlmutter Cancer Center
New York, NY 
 
     
9:45 am CT GS3-04.   Double-blind placebo (PBO)-controlled randomized phase III trial evaluating first-line ipatasertib (IPAT) combined with paclitaxel (PAC) for PIK3CA/AKT1/PTEN-altered locally advanced unresectable or metastatic triple-negative breast cancer (aTNBC): primary results from IPATunity130 Cohort A  
  Dent R, Kim S, Oliveira M, Barrios C, O’Shaughnessy J, Isakoff SJ, Saji S, Freitas-Junior R, Philco M, Bondarenko I, Lian Q, Bradley D, Hinton H, Wongchenko MJ, Mani A, Turner N. National Cancer Center, Singapore, Singapore; Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea, Republic of; Vall d’Hebron University Hospital, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain; Latin American Cooperative Oncology Group, Porto Alegre RS, Brazil; Baylor University Medical Center, Texas Oncology, US Oncology, Dallas, TX; Massachusetts General Hospital, Boston, MA; Fukushima Medical University Hospital, Fukushima City, Japan; Hospital Araujo Jorge, Goiania, Brazil; Unidad de Investigación, Instituto de Oncología y Radioterapia, Clínica Ricardo Palma, San Isidro, Peru; City Clinical Hospital No. 4, Dnipropetrovsk, Ukraine; Genentech, Inc., South San Francisco, CA; Roche Products Ltd, Welwyn Garden City, United Kingdom; F Hoffmann-La Roche Ltd, Basel, Switzerland; The Royal Marsden NHS Foundation Trust, and Breast Cancer Now Research Centre, The Institute of Cancer Research, London, United Kingdom.   
     
10:00 am CT GS3-05.  Classification of triple negative breast cancer (TNBC) by DNA Damage Immune Response (DDIR) signature and Homologous Recombination Deficiency (HRD) status: Analysis of SWOG S9313 adjuvant trial    
  Stecklein SR, Barlow W, Pusztai L, Timms K, Kennedy R, Badve S, Gökmen-Polar Y, Porter P, Linden H, Tripathy D, Hortobagyi GN, Godwin AK, Thompson A, Hayes D, Sharma P. University of Kansas Medical Center, Kansas City, KS; SWOG Statistical Center, Seattle, WA; Yale Cancer Center, New Haven, CT; Myriad Genetics, Inc., Salt Lake City, UT; Almac Group, Craigavon, United Kingdom; Indiana University School of Medicine, Indianapolis, IN; Fred Hutchinson Cancer Research Center, Seattle, WA; University of Washington, Seattle, WA; The University of Texas MD Anderson Cancer Center, Houston, TX; Baylor College of Medicine, Houston, TX; University of Michigan, Ann Arbor, MI; University of Kansas Medical Center, Westwood, KS.   
     
10:15 am CT GS3-06.  Biomarker evaluation in the phase 3 ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer   
  Hurvitz SA, Tolaney SM, Punie K, Loirat D, Oliveira M, Kalinsky K, Zelnak A, Aftimos P, Dalenc F, Sardesai S, Hamiltion E, Sharma P, Recalde S, Gil EC, Traina T, O'Shaughnessy J, Cortés J, Tsai M, Vahdat L, Diéras V, Carey L, Rugo HS, Goldenberg DM, Hong Q, Olivo M, Itri LM, Bardia A. University of California, Los Angeles, Jonsson Comprehensive Cancer Center, Los Angeles, CA; Dana-Farber Cancer Institute, Boston, MA; University Hospitals Leuven, Leuven, Belgium; Institut Curie, Paris, France; Hospital Universitari Vall d'Hebron, Barcelona, Spain; Columbia University Medical Center, New York, NY; Northside Hospital, Atlanta, GA; Institut Jules Bordet, Brussels, Belgium; Institut Claudius Regaud, Toulouse, France; The Ohio State University Wexner Medical Center, Columbus, OH; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN; University of Kansas Cancer Center - The Richard and Annette Bloch Cancer Care Pavilion, Kansas City, KS; Institut Catala d'Oncologia Hospitalet, Barcelona, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; Memorial Sloan Kettering Cancer Center, New York, NY; Texas Oncology - Baylor Charles A. Sammons Cancer Center, Dallas, TX; IOB Institute of Oncology, Quiron Group, Madrid & Barcelona, Madrid, Spain; VPCI Oncology Research, Minneapolis, MN; Centre Eugène-Marquis, Rennes, France; University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC; University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Immunomedics, Morris Plains, NJ; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA.   
     
10:30 am CT GS3-07.  Identifying patients whose symptoms are under-recognized during breast radiotherapy: comparison of patient and physician reports of toxicity in a multicenter cohort    
  Jagsi R, Griffith KA, Vicini F, Boike T, Dominello M, Gustafson G, Hayman JA, Moran JM, Radawski J, Walker E, Pierce LJ, on behalf of MROQC, the Michigan Radiation Oncology Quality Consortium. University of Michigan, Ann Arbor, MI; MHP Radiation Oncology, Pontiac, MI; MHP Radiation Oncology, Troy, MI; Karmanos, Detroit, MI; Beaumont, Troy, MI; West Michigan Cancer Center, Kalamazoo, MI; Henry Ford, Detroit, MI.   
     
10:45 am CT GS3-08.  Persistent controlled substance use following mastectomy with reconstruction surgery    
  Cogan JC, Raghunathan RR, Beauchemin MP, Accordino MK, Melamed A, Wright JD, Hershman DL. Columbia University Division of Hematology/Oncology, New York, NY; Columbia University Division of Gynecologic Oncology, New York, NY.   
     
11:00 am CT GS3-09.  Chances of pregnancy after breast cancer, reproductive and disease outcomes: a systematic review and meta-analysis    
  Blondeaux E, Perachino M, Bruzzone M, Anderson RA, De Azambuja E, Poorvu PD, Kim HJ, Villarreal-Garza C, Pistilli B, Vaz-Luis I, Saura C, Ruddy KJ, Franzoi MA, Sertoli C, Ceppi M, Azim Jr. HA, Amant F, Demeestere I, Del Mastro L, Partridge AH, Pagani O, Peccatori FA, Lambertini M. IRCCS Ospedale Policlinico San Martino, Genova, Italy; The Queen's Medical Research Institute, The University of Edinburgh, Edinburgh, United Kingdom; Institut Jules Bordet, Université Libre de Bruxelles (U.L.B.), Brussels, Belgium; Dana-Farber Cancer Institute, Boston, MA; Asan Medical Center, Seoul, Korea, Republic of; Hospital Zambrano Hellion, Tecnologico de Monterrey, San Pedro Garza Garcia, Mexico; Institut Gustave Roussy, Villejuif, France; Vall d´Hebron University Hospital (HUVH), Vall d´Hebron Institute of Oncology (VHIO), Barcelona, Spain; Mayo Clinic, Rochester, MN; University of Genova, Genova, Italy; Hospital Zambrano Hellion, Tecnologico de Monterrey, San Pedro Garza Garcia, Mexico; Netherlands Cancer Institute and Amsterdam University Medical Centers, Amsterdam, Netherlands; Erasme Hospital, Université Libre de Bruxelles (U.L.B.), Brussels, Belgium; Breast Unit and Institute of Oncology of Southern Switzerland, Geneva University Hospitals, Swiss Group for Clinical Cancer Research, Lugano, Switzerland; European Institute of Oncology IRCCS, European School of Oncology, Milano, Italy.   
     
11:15 am CT GS3-10.  Partitioning of cancer therapeutics in nuclear condensates    
  Klein I, Boija A, Afeyan L, Hawken SW, Fan M, Dall'Agnese A, Oksuz O, Henninger J, Shrinivas K, Sabari B, Sagi I, Clark V, Platt J, Kar M, McCall P, Zamudio A, Mantiega J, Coffey E,  Li C, Hannett N, Guo Y, Decker TM, Lee T, Zhang T, Weng J, Taatjes D, Chakraborty A, Sharp P, Chang YT, Hyman A, Gray N, Young R. Dana Farber Cancer Institute, Boston, MA; Whitehead Institute, Cambridge, MA; Massachusetts Institute of Technology, Cambridge, MA; Massachusetts General Hospital, Boston, MA; Max Plank Institute, Dresden, Germany; University of Colorado, Boulder, CO; POSTECH, Pohang, Republic of Korea.  
     
10:00 am - 3:00 pm CT EXHIBITS  
     
11:30 am - 1:00 pm CT NETWORKING WITH THE EXPERTS  
  Networking with the Experts will be offered as a “can’t miss” interactive opportunity for young and established investigators alike at the 2020 Virtual San Antonio Breast Cancer Symposium. The event will start with panel discussions followed by smaller breakout discussions for attendees to interact directly with research luminaries. There will be no formal program, but participation in one of the groups will be a fun opportunity to socialize and network with colleagues and potential collaborators working in your area, as well as some of the most respected investigators in the breast cancer research community.

No pre-registration is required.
 
11:30 am - 11:35 am CT Introduction
Eric Winer, Dana-Farber Cancer Institute, Boston, MA
 
11:35 am - 12:15 pm CT Concurrent Panel Discussions  
  Treatment Optimization trials: What makes sense, what is useless and what's crazy
Moderator: Eric Winer, Dana-Farber Cancer Institute, Boston, MA
 
  Panelists:
Lisa Carey, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC
Liz Garrett-Mayer, ASCO, Alexandria, VA
Tari A. King, Dana-Farber Cancer Institute, Boston, MA
Priyanka Sharma, University of Kansas Medical Center, Kansas City, KS
Sara M. Tolaney, Dana-Farber Cancer Institute, Boston, MA
Julia R. White, The Ohio State University Comprehensive Cancer Center, Columbus, OH
Antonio C. Wolf, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD
 
  Preclinical modeling for therapeutic outcomes
Moderator: Suzanne Fuqua, Baylor College of Medicine, Houston, TX
 
  Panelists:
Andrew Ewald, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD
Cyrus Ghajar, Fred Hutchinson Cancer Research Center, Seattle, WA
Jos Jonkers, Netherlands Cancer Institute, Amsterdam, Netherlands
Michael T. Lewis, Baylor College of Medicine, Houston, TX
Senthil Muthuswamy, Beth Israel Deaconess Medical Center, Boston, MA
Carol A. Sartorius, University of Colorado Anschutz Medical Campus, Aurora, CO
Alana Welm, University of Utah Huntsman Cancer Institute, Salt Lake City, UT
 
12:15 pm - 1:00 pm CT Attendees will be able to join up to 2 breakout groups for in-depth conversations with each other and the Panelists. Panelists will be paired together in breakout rooms as follows.  
  1. Clinical
Eric Winer and Lisa Carey
Liz Garrett-Mayer and Sara M. Tolaney
Priyanka Sharma and Julia R. White
Tari King and Antonio Wolfe

2. Translational/Basic
Andrew Ewald and Alana Welm
Jos Jonkers and Michael T. Lewis
Senthil Muthuswamy and Carol A. Sartorius
Suzanne Fuqua and Cyrus Ghajar
 
     
 11:30 am - 1:00 pm CT CASE DISCUSSION 2
Moderator: Mothaffar Rimawi, MD
Baylor College of Medicine
Houston, TX
 
  Panel Members
Stephen Johnston
The Royal Marsden
London, United Kingdom

Lisa A. Carey, MD
University of North Carolina
Chapel Hill, NC

Swati Kulkarni, MD
Northwestern Medicine
Chicago, IL

Wendy A. Woodward, MD, PhD 
UT MD Anderson Cancer Center
Houston, TX

Andrea Richardson, MD, PhD
Johns Hopkins Medicine
Washington, DC

Ginny Mason, BSN, RN
Inflammatory Breast Cancer Research Foundation
West Lafayette, IN
 
     
12:30 pm - 1:00 pm CT BREAK   
 
 
1:00 pm - 2:15 pm CT

SPOTLIGHT SESSION 4: Updates on Strategies to Refine Management of the Axilla

 
 

Chair: Abigail Caudle, MD
UT MD Anderson Cancer Center
Houston, TX

Management of the axilla in early stage disease
Melissa Pilewski, MD
Memorial Sloan Kettering Cancer Center
New York, NY

Management of the clinically node positive axilla
Viviana Galimberti, Dr. Med
European Institute of Oncology
Milano, Italy

Refining the role of regional nodal irradiation
Jennifer Bellon, MD
Dana-Farber Cancer Institute
Boston, MA

 
     
  SPOTLIGHT SESSION 7: Examining Early Events: Novel Models and Neoadjuvant Events 
 
 

Chair: Joyce Slingerland, MD
Georgetown University
Washington, DC

Novel models
Shom Goel, MD, PhD
Peter MacCallum Cancer Centre
Melbourne, Australia

Neoadjuvant trials
Adrian Lee, PhD
University of Pittsburgh
Pittsburgh, PA

 
     
2:15 pm - 3:30 pm CT SPOTLIGHT SESSION 5: Current Concepts and Controversies in Ductal Carcinoma in Situ (DCIS)  
 

Chair: Tari A. King, MD
Dana-Farber Cancer Institute
Boston, MA

Epidemiology of disease progression
Swati Kulkarni, MD
Northwestern Medicine
Chicago, IL

Refining risk prediction and decision making
Eileen Rakovitch, MD
Sunnybrook Odette Cancer Centre
Toronto, Canada

Biologic insights and changes in the parous breast
Kornelia Polyak, MD, PhD
Dana-Farber Cancer Institute
Boston, MA

 
     
  SPOTLIGHT SESSION 8: Endocrine Resistance: Emerging Mechanisms and Therapies   
 

Chair: Carol Lange, PhD
Masonic Cancer Center
University of Minnesota
Minneapolis, MN

Novel mechanisms
Sarat Chandarlapaty, MD
Memorial Sloan Kettering Cancer Center
New York, NY

Emerging new therapies
Ingrid A. Mayer, MD, MSCI
Vanderbilt University Medical Center
Nashville, TN 

 
     
3:30 pm - 4:45 pm CT SPOTLIGHT SESSION 6: Novel Approaches to Pathology and Imaging 
                          

Co-Chairs: Karla Sepulveda, MD
Baylor College of Medicine
Houston, TX
and
Kalliopi P. Siziopikou, MD, PhD
Northwestern University
Chicago, IL

Novel methods in breast cancer diagnosis
Michael D. Feldman, MD, PhD
University of Pennsylvania,
Philadelphia, PA

MRI applications and radiomics
Susan P. Weinstein, MD
Penn Medicine
Philadelphia, PA

Novel imaging agents
Haydee Ojeda-Fournier, MD
UC San Diego Health
San Diego, CA                 

 
     
  SPOTLIGHT SESSION 9: Challenging Indications and Innovative Approaches for Biomarkers   
 

Chair: W. Fraser Symmans, Mb ChB
UT MD Anderson Cancer Center
Houston, TX

(Neo) adjuvant
Christos Sotiriou, MD, PhD
Institut Jules Bordet, Université Libre de Bruxelles (ULB)
Brussels, Belgium

Metastatic
Bryan P. Schneider, MD
Indiana University School of Medicine
Indianapolis, IN

 
 
7:30 pm CT OPEN SATELLITE EVENT presented by Clinical Care Options, LLC

Evolving Clinical Considerations for Breast Cancer Brain Metastases: Expert Case Discussions

For more information and to register for this event, click on the link below:
www.clinicaloptions.com/CNSDecember2020 
 
     
7:30 pm CT OPEN SATELLITE EVENT presented by Research to Practice

Beyond the Guidelines: Clinical Investigator Perspectives on the Management of Patients with HER2-Positive Breast Cancer — Part 1 of a 2-Part CME Satellite Symposia Series

For more information and to register for this event, click on the link below:
http://www.researchtopractice.com/Meetings/SA2020
 
 
Tuesday | Wednesday | Wednesday (OnDemand) | Thursday | Friday
 
In collaboration with  Astro     and     SSO